Generali Investments Management Co LLC Sells 1,982 Shares of Stryker Co. (NYSE:SYK)

Generali Investments Management Co LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 16.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,086 shares of the medical technology company's stock after selling 1,982 shares during the quarter. Stryker comprises 1.1% of Generali Investments Management Co LLC's holdings, making the stock its 21st largest holding. Generali Investments Management Co LLC's holdings in Stryker were worth $3,755,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. J. W. Coons Advisors LLC lifted its holdings in shares of Stryker by 0.7% in the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after purchasing an additional 26 shares in the last quarter. Mascoma Wealth Management LLC increased its position in Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after purchasing an additional 27 shares during the last quarter. Opal Wealth Advisors LLC increased its position in Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after purchasing an additional 28 shares during the last quarter. Lindbrook Capital LLC increased its position in Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after purchasing an additional 28 shares during the last quarter. Finally, Capital & Planning LLC grew its stake in Stryker by 3.6% during the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock worth $304,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Price Performance

Shares of SYK traded up $1.05 during mid-day trading on Friday, hitting $384.15. The company's stock had a trading volume of 709,048 shares, compared to its average volume of 1,331,290. The firm has a 50-day moving average price of $370.10 and a 200 day moving average price of $376.03. The stock has a market capitalization of $146.63 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 2.93 and a beta of 0.91. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. During the same period last year, the company posted $2.50 earnings per share. The business's revenue for the quarter was up 11.9% on a year-over-year basis. On average, research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio is currently 45.41%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SYK shares. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a report on Monday, May 5th. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $427.30.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.